Genticel granted five new patents in the US and Asia during first half of 2014

31-Jul-2014 - France

Genticel has been granted five patents in major territories since the beginning of 2014. These patents consolidate Genticel’s product pipeline in important emerging and mature pharmaceutical markets.

The patents US 8628779, IN 258906 and KR 10-1382250, granted in the USA, India and South Korea respectively on January 14, February 14 and April 1 claim a recombinant protein carrying human papillomavirus (HPV) epitopes inserted in an adenylate cyclase protein or fragments thereof. They encompass granted claims protecting Genticel’s candidate therapeutic vaccine, ProCervix, and contain claims that also cover other HPV therapeutic vaccines with multiple antigens such as Genticel’s follow-on candidate product ‘Multivalent HPV’.

In addition, the patent US 8637039, granted on January 28, describes an HPV infection treatment comprising proprietary methods currently used in the ongoing Phase II efficacy trial with the lead candidate, ProCervix.
 
Lastly, JP 5496669 was granted in Japan on March 14, 2014. It protects a composition for eliciting a specific cytotoxic T cell response, comprising a lympho-ablative compound and a molecule (containing an antigenic sequence) that targets professional antigen-presenting cells. The patent specification is particularly appropriate for administration of ProCervix and related immunotherapeutics in combination with immunosuppressive drugs for use in advanced disease indications such as cervical carcinoma, HPV-associated anal and oropharyngeal cancers.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?